Withdrawal from Treatment as an Outcome in the ISOLDE Study of COPD

Chest

Volumn 124, Issue 4, 2003, Pages 1350-1356

  Calverley, Peter M A ^a   Spencer, Sally ^b   Willits, Lisa ^d   Burge, P Sherwood ^c   Jones, Paul W ^b  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

COPD; Exacerbation; Fluticasone propionate; Patient withdrawal

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE; PLACEBO; PREDNISOLONE; SALBUTAMOL;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEVICE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEALTH CENTER; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; UNITED KINGDOM;

EID: 0142010545     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.124.4.1350     Document Type: Article

References (23)

1. Greening AP, Wind P, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344:219-224
2. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma: Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405-1411
3. Chervinsky P, Van As A, Bronsky EA, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol 1994; 94:676-683
4. Nelson HS, Busse WW, DeBoisblanc BP, et al. Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma. J Allergy Clin Immunol 1999; 103: 267-275
5. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155:1283-1289
6. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353:1819-1823
7. Pauwels RA, Lofdahl C-G, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340:1948-1953
8. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297-1303
9. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343:1902-1909
10. Davies L, Angus RM, Calverley PMA. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354:456-460
11. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340:1941-1947
12. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152:S77-S120
13. Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:1256-1276
14. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure for chronic airflow limitation: the St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-1327.
15. Jones PW, Quirk FH, Baveystock CM. The St. George's Respiratory Questionnaire. Respir Med 1991; 85(suppl B): 25-31
16. Jones PW, Lasserson D. Relationship between change in SGRQ score and patient's perception of treatment efficacy after one year of therapy with nedocromil sodium [abstract]. Am Rev Respir Crit Care Med 1994; 149:A211
17. Meecham-Jones DJ, Paul EA, Jones PW, et al. Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. Am J Respir Crit Care Med 1995; 152:538-544
18. Ware J, Sherbourne C. The MOS 36-item short form health survey (SF36): 1. Conceptual framework and item selection. Med Care 1992; 30:473-481
19. Brazier J, Harper R, Jones N, et al. Validating the SF36 health survey questionnaire: a new outcome measure for primary care. BMJ 1992; 305:160-164
20. Jarad NA, Wedzicha JA, Burge PS, et al. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. Respir Med 1999; 93:161-168
21. Spencer S, Calverley PMA, Burge PS, et al. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1991; 163:122-128
22. Osman IM, Godden DJ, Friend JA, et al. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 1997; 52:67-71
23. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:1418-1422